RxDoctor Payments Data

Roel Contreras

Physician Assistant · Mission, TXNPI 1336353390

Payments from drug & device makers

$1,442in general payments, 2019–2025

Across 55 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$635
  • Lilly USA, LLC$163
  • Abbott$148
  • GSK$116
  • Pfizer$100
  • Regeneron Healthcare Solutions, Inc.$63
  • plus $216 from 8 others

What the payments were for

  • Food & beverage$1,442100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,442 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$23,314
Medicare patients
88
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$22,894
OzempicSemaglutide21$20,271
EliquisApixaban14$13,015
JanuviaSitagliptin Phosphate12$12,906
Olmesartan Medoxomil67$1,143
Atorvastatin Calcium103$959
Rosuvastatin Calcium68$887
Levothyroxine Sodium69$792
Celecoxib22$782
Omeprazole47$520
SynthroidLevothyroxine Sodium12$517
Amlodipine Besylate90$513
Diclofenac Sodium11$463
Fluticasone Propionate20$460
Tamsulosin Hcl25$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23$22,89425 claims
Novo NordiskOzempic$635$20,27121 claims
PfizerEliquis$100$13,01514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →